5. Veatch AL, Carson LF, Ramakrishnan S (1995) Phenotypic variations and differential migration of NIH:OVCAR-3 ovarian carcinoma cells isolated from athymic mice. Clin Exp Metastasis 13: 165–172. 6. Overington JP, Al-Lazikani B, Hopkins AL (2006) How many drug targets are there? Nat Rev Drug Discov 5: 993–996. 7. Houseknecht KL, Cole BM, Steele PJ (2002) Peroxisome proliferator-activated receptor gamma (PPARgamma) and its ligands: a review. Domest Anim Endocrinol 22: 1–23. 8. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, et al. (1997) The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 272: 18779–18789. 9. Wang X, Southard RC, Kilgore MW (2004) The increased expression of peroxisome proliferator-activated receptor-gamma1 in human breast cancer is mediated by selective promoter usage. Cancer Res 64: 5592–5596. 10. Berger J, Bailey P, Biswas C, Cullinan CA, Doebber TW, et al. (1996) Thiazolidinediones produce a conformational change in peroxisomal prolif- erator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 137: 4189–4195. 11. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, et al. (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270: 12953–12956. 12. Panigrahy D, Huang S, Kieran MW, Kaipainen A (2005) PPARgamma as a therapeutic target for tumor angiogenesis and metastasis. Cancer Biol Ther 4: 687–693. 13. Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, et al. (2003) Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat 79: 391–397. 14. Demetri GD, Fletcher CD, Mueller E, Sarraf P, Naujoks R, et al. (1999) Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A 96: 3951–3956. 15. Ondrey F (2009) Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention. Clin Cancer Res 15: 2–8. 16. Koszewski NJ, Herberth J, Malluche HH (2010) Retinoic acid receptor gamma 2 interactions with vitamin D response elements. J Steroid Biochem Mol Biol. 17. Zhang Z, Kovalenko P, Cui M, Desmet M, Clinton SK, et al. (2010) Constitutive activation of the mitogen-activated protein kinase pathway impairs vitamin D signaling in human prostate epithelial cells. J Cell Physiol. 18. Gurnell M, Wentworth JM, Agostini M, Adams M, Collingwood TN, et al. (2000) A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma- mediated adipogenesis. J Biol Chem 275: 5754–5759. 19. Zaytseva YY, Wang X, Southard RC, Wallis NK, Kilgore MW (2008) Down- regulation of PPARgamma1 suppresses cell growth and induces apoptosis in MCF-7 breast cancer cells. Mol Cancer 7: 90. 20. Yang YC, Tsao YP, Ho TC, Choung IP (2007) Peroxisome proliferator- activated receptor-gamma agonists cause growth arrest and apoptosis in human ovarian carcinoma cell lines. Int J Gynecol Cancer 17: 418–425. 21. Vignati S, Albertini V, Rinaldi A, Kwee I, Riva C, et al. (2006) Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells. Neoplasia 8: 851–861. 22. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55–63. 23. Soller M, Drose S, Brandt U, Brune B, von Knethen A (2007) Mechanism of thiazolidinedione-dependent cell death in Jurkat T cells. Mol Pharmacol 71: 1535–1544. 24. Hauser S, Adelmant G, Sarraf P, Wright HM, Mueller E, et al. (2000) Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation. J Biol Chem 275: 18527–18533. 25. Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, et al. (2002) PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 110: 923–932. 26. Seargent JM, Yates EA, Gill JH (2004) GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation. Br J Pharmacol 143: 933–937. 27. Blanquicett C, Roman J, Hart CM (2008) Thiazolidinediones as anti-cancer agents. Cancer Ther 6: 25–34. 28. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, et al. (1998) Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 58: 3344–3352. 29. Mustafa A, Kruger WD (2008) Suppression of tumor formation by a cyclooxygenase-2 inhibitor and a peroxisome proliferator-activated receptor gamma agonist in an in vivo mouse model of spontaneous breast cancer. Clin Cancer Res 14: 4935–4942. 30. Gras D, Chanez P, Urbach V, Vachier I, Godard P, et al. (2009) Thiazolidinediones induce proliferation of human bronchial epithelial cells PPARc Ligands Differentially Impact OVCAR Cells through the GPR40 receptor. Am J Physiol Lung Cell Mol Physiol 296: L970–978. 31. Saiki M, Hatta Y, Yamazaki T, Itoh T, Enomoto Y, et al. (2006) Pioglitazone inhibits the growth of human leukemia cell lines and primary leukemia cells while sparing normal hematopoietic stem cells. Int J Oncol 29: 437–443. 32. Valentiner U, Carlsson M, Erttmann R, Hildebrandt H, Schumacher U (2005) Ligands for the peroxisome proliferator-activated receptor-gamma have inhibitory effects on growth of human neuroblastoma cells in vitro. Toxicology 213: 157–168. 33. Yang FG, Zhang ZW, Xin DQ, Shi CJ, Wu JP, et al. (2005) Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines. Acta Pharmacol Sin 26: 753–761. 34. Yang Z, Bagheri-Yarmand R, Balasenthil S, Hortobagyi G, Sahin AA, et al. (2003) HER2 regulation of peroxisome proliferator-activated receptor gamma (PPARgamma) expression and sensitivity of breast cancer cells to PPARgamma ligand therapy. Clin Cancer Res 9: 3198–3203. 35. Clay CE, Namen AM, Atsumi G, Trimboli AJ, Fonteh AN, et al. (2001) Magnitude of peroxisome proliferator-activated receptor-gamma activation is associated with important and seemingly opposite biological responses in breast cancer cells. J Investig Med 49: 413–420. 36. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, et al. (1998) Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A 95: 8806–8811. 37. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, et al. (1998) Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1: 465–470. 38. Nakashiro KI, Hayashi Y, Kita A, Tamatani T, Chlenski A, et al. (2001) Role of peroxisome proliferator-activated receptor gamma and its ligands in non- neoplastic and neoplastic human urothelial cells. Am J Pathol 159: 591–597. 39. Ohta K, Endo T, Haraguchi K, Hershman JM, Onaya T (2001) Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 86: 2170–2177. 40. Wei S, Yang HC, Chuang HC, Yang J, Kulp SK, et al. (2008) A novel mechanism by which thiazolidinediones facilitate the proteasomal degradation of cyclin D1 in cancer cells. J Biol Chem 283: 26759–26770. 41. Berger J, Moller DE (2002) The mechanisms of action of PPARs. Annu Rev Med 53: 409–435. 42. Camp HS, Li O, Wise SC, Hong YH, Frankowski CL, et al. (2000) Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone. Diabetes 49: 539–547. 43. Rangwala SM, Lazar MA (2004) Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol Sci 25: 331–336. 44. Talbert DR, Allred CD, Zaytseva YY, Kilgore MW (2008) Transactivation of ERalpha by Rosiglitazone induces proliferation in breast cancer cells. Breast Cancer Res Treat 108: 23–33. 45. Faich GA, Moseley RH (2001) Troglitazone (Rezulin) and hepatic injury. Pharmacoepidemiol Drug Saf 10: 537–547. 46. Smith U (2001) Pioglitazone: mechanism of action. Int J Clin Pract Suppl: 13–18. 47. Burns KA, Vanden Heuvel JP (2007) Modulation of PPAR activity via phosphorylation. Biochim Biophys Acta 1771: 952–960. 48. Choi JH, Banks AS, Estall JL, Kajimura S, Bostrom P, et al. (2010) Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 466: 451–456. 49. Melichar B, Konopleva M, Hu W, Melicharova K, Andreeff M, et al. (2004) Growth-inhibitory effect of a novel synthetic triterpenoid, 2-cyano-3,12- dioxoolean-1,9-dien-28-oic acid, on ovarian carcinoma cell lines not dependent on peroxisome proliferator-activated receptor-gamma expression. Gynecol Oncol 93: 149–154. 50. Jiang G, Dallas-Yang Q, Li Z, Szalkowski D, Liu F, et al. (2002) Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPARgamma agonists. Diabetes 51: 2412–2419. 51. Jarrar MH, Baranova A (2007) PPARgamma activation by thiazolidinediones (TZDs) may modulate breast carcinoma outcome: the importance of interplay with TGFbeta signalling. J Cell Mol Med 11: 71–87. 52. Shigeto T, Yokoyama Y, Xin B, Mizunuma H (2007) Peroxisome proliferator- activated receptor alpha and gamma ligands inhibit the growth of human ovarian cancer. Oncol Rep 18: 833–840. 53. Vindelov LL, Christensen IJ, Nissen NI (1983) A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3: 323–327. 54. Qi C, Zhu Y, Reddy JK (2000) Peroxisome proliferator-activated receptors, coactivators, and downstream targets. Cell Biochem Biophys 32 Spring. pp 187–204. 55. Allred CD, Kilgore MW (2005) Selective activation of PPARgamma in breast, colon, and lung cancer cell lines. Mol Cell Endocrinol 235: 21–29. 56. R (2005) Development Core Team, R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria, ISBN 3-900051-07-0. Miscellaneous. PLoS ONE | www.plosone.org 14 January 2011 | Volume 6 | Issue 1 | e16179